Navigation Links
Amgen to Present Pivotal Data From Four Phase 3 Studies at the ECCO 15 - ESMO 34 Congress
Date:9/16/2009

nd deep development program demonstrates Amgen's commitment to researching and delivering pioneering medicines to patients with unmet medical needs. Amgen is studying denosumab in numerous tumor types across the spectrum of cancer induced bone disease. Over 11,000 patients have been enrolled in the denosumab oncology clinical trials testing the drug for bone loss and destruction associated with cancer treatment-induced bone loss in breast and prostate cancers, for the prevention of skeletal related events due to the spread of cancer to the bone in multiple myeloma and multiple solid tumors, and for its potential to delay bone metastases in prostate cancer.

In two phase 3 skeletal related events studies reported to date, the incidence of adverse events and serious adverse events was consistent with what has previously been reported for denosumab and Zometa. Osteonecrosis of the jaw (ONJ) was seen infrequently in both treatment groups.

About Vectibix

Vectibix is the first fully human anti-EGFR approved by the U.S. Food and Drug Administration (FDA) for the treatment of mCRC. Vectibix was approved in the United States in September 2006 as a monotherapy for the treatment of patients with EGFR expressing mCRC after disease progression on or following fluoropyrimidine-, oxaliplatin-, and irinotecan-containing chemotherapy regimens.

In December 2007, the European Commission granted a conditional marketing authorization for Vectibix as monotherapy for the treatment of patients with EGFR-expressing mCRC with wild-type KRAS genes after failure of standard chemotherapy regimens. Vectibix has been launched in over 20 countries, including Switzerland, Australia and Canada. Applications in the rest of the world are pending.

The effectiveness of Vectibix as a single agent for the treatment of EGFR-expressing, metastatic colorectal carcinoma is based on progression-free survival. Currently no
'/>"/>

SOURCE Amgen
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine news :

1. Major Pharma Clinical Case Studies From Amgen, AstraZeneca, GSK, Intermune, Cephalon Inc, Sunesis Pharmaceuticals and Dartmouth Medical School During Fall Clinical Focused Programs
2. InteKrin Therapeutics, Inc. Appoints Former Amgen Clinical Development Executive Chief Medical Officer
3. OmniPod(R) Insulin Management System Lets Team Type 1 Members Focus on Competing at Amgen Tour of California
4. Amgen to Present at the Barclays Capital Global Healthcare Conference
5. Amgen Announces Webcast of 2009 First Quarter Financial Results
6. Amgens First Quarter 2009 Adjusted Earnings Per Share Decreased 4 Percent to $1.08
7. Amgen and ONSEdge Partner With Cancer Survivor Jan Ping for New Campaign
8. Amgen to Present at the Deutsche Bank 34th Annual Healthcare Conference
9. Amgen Highlights Data to Be Presented at ASCO
10. Amgens Denosumab and Eli Lillys Forteo/Forsteo Will Drive Robust Annual Growth in the Osteoporosis Drug Market From 2013 to 2018
11. Loyola fellow receives Amgen grant to study treatments for older leukemia patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)... 28, 2014 According to the Drama Method ... relationship guide that helps women easily get the attention of ... Vkool reveals in its review that this book can teach ... their man. The book also instructs them how to conquer ... in its Drama Method review that this book is divided ...
(Date:7/28/2014)... Dr. Alan Xenakis, MD announced today the release of ... new book, DOC X MD Funny Feelings translates ... style with humor and medical accuracy. The book is creatively ... answers to those age-old questions that most folks are embarrassed ... do mosquitoes bite some and not others? Why do folks ...
(Date:7/27/2014)... Recently, Wdsshop.de, a reliable online supplier of women’s ... prom dresses on its website. Now, all these ... 58% off. , “We are pleased to add the new ... specially created for those who are in need of fashionable ... in style. I think our clients will love them. Ladies, ...
(Date:7/27/2014)... shown that a powerful drug given at the time ... early risk of rejection, but that it also allows ... used after the operation. , The key results are ... the World Transplant Congress in San Francisco today. They ... the powerful combinations of treatments used to prevent early ...
(Date:7/27/2014)... why medication to treat asthma and pneumonia can become ineffective. ... that drugs widely used to treat lung diseases work with ... which is caused by an infection, affects around 1 in ... young children, the elderly, smokers and those with an underlying ... the UK are affected by asthma and the NHS spends ...
Breaking Medicine News(10 mins):Health News:The Drama Method Pdf Review Exposes Aaron Fox's Relationship Guide – Vkool.com 2Health News:The Drama Method Pdf Review Exposes Aaron Fox's Relationship Guide – Vkool.com 3Health News:New Book by Alan P. Xenakis, MD Reveals Mind and Body Mysteries 2Health News:Wdsshop.de Unveils New Prom Dresses To Expand The Online Market 2Health News:Kidney transplant drug halves the early risk of rejection and allows less toxic treatment 2Health News:Kidney transplant drug halves the early risk of rejection and allows less toxic treatment 3Health News:Drugs used to treat lung disease work with the body clock 2
... this Valentine,s Day and give the friends and family ... gift that will satisfy,their sweet tooth, warm their heart ... new Organic Chocolate Single Serve is a deep chocolate,nectar ... all of the,fat, cholesterol and calories," said Pam Dietz, ...
... A new company has joined the fight against MRSA ... have launched a new company, Inspiralis Ltd, based around ... enzymes that help DNA molecules to unravel and wind ... , DNA becomes tangled as a result of ...
... Nearly 90,000 Annual ... ... provider of,point-of-care charge capture technologies, today announced that its,customer, the ... Infusion Services Module., The Module, an extension of MedAptus, ...
... of Men With Erectile Dysfunction Are Smokers, NEW ... image and attractiveness, it does the exact opposite when ... According to recent studies, 60-percent of all men who ... partners burning,for more passion. In an effort to dramatically ...
... of the Cancion(R) System in Patients ... Hospitalized with Heart Failure, ... products company developing and marketing devices to,treat heart failure, announced ... Breaking Clinical Trial presentation at the,upcoming annual American College of ...
... Noyes announced today that,the firm represented The Riverside Company ... to Halyard Capital. The management team will,continue to have ... transaction,were not disclosed., "This is an excellent match ... winning healthcare and information franchise," said,Tom O,Connor, the Berkery ...
Cached Medicine News:Health News:Give Vitasoy's 'Liquid Love' for Heart Month! 2Health News:DNA with a twist: New company to search for cancer drugs and antibiotics 2Health News:Dana-Farber Cancer Institute Completes Deployment of MedAptus' Infusion Services Module 2Health News:Dana-Farber Cancer Institute Completes Deployment of MedAptus' Infusion Services Module 3Health News:The Best Way to Stoke Your Valentine's Fire: Don't Light Up 2Health News:Orqis(R) Medical's MOMENTUM Trial Abstract Accepted for Late Breaking Clinical Trial Presentation at the American College of Cardiology Annual Meeting 2Health News:Berkery Noyes Represented The Riverside Company on the Sale of HCPro Holdings, Inc. to Halyard Capital, LLC 2Health News:Berkery Noyes Represented The Riverside Company on the Sale of HCPro Holdings, Inc. to Halyard Capital, LLC 3
(Date:7/25/2014)... and Tobago , July 25, 2014 /PRNewswire/ ... Trinidad & Tobago Ministry of Health approved the ... that significantly increases the cure rate from Hepatitis ... with the genotype 1 virus. Telaprevir is available ... trade brand INCIVO®. Photo - ...
(Date:7/25/2014)... July 25, 2014  Acsis Inc., the market ... serialization solutions, has recently posted an article, ... current and future needs for companies, extended supply ... supply chain model no longer work today.  The ... the growth of mobile technology, machine to machine ...
(Date:7/25/2014)... July 25, 2014 According to ... "Global and China Insulin Market (Rapid-Acting, Short-Acting, Intermediate-Acting, Long-Acting, ... Share, Growth, Trends and Forecast (Value and Volume), 2013 ... USD 19.99 billion in 2012 and is expected to ... 2019 to reach USD 32.24 billion in 2019. ...
Breaking Medicine Technology:The Hepatitis C virus is the main cause of liver transplant in the world 2The Hepatitis C virus is the main cause of liver transplant in the world 3Acsis Addresses Questions on the Modern Supply Chain 2Global Insulin Market Expected to Reach USD 32.24 Billion Globally in 2019: Transparency Market Research 2Global Insulin Market Expected to Reach USD 32.24 Billion Globally in 2019: Transparency Market Research 3Global Insulin Market Expected to Reach USD 32.24 Billion Globally in 2019: Transparency Market Research 4
... by March of Dimes Grantee Offers Hope for Treatment ... new gene-based,technique has successfully prevented a rare craniofacial birth ... the same disorder, according,to new research funded in part ... is being published in the journal Nature Medicine,demonstrates the ...
... /Xinhua-PRNewswire-FirstCall/ -- Lotus Pharmaceuticals,Inc. (OTC Bulletin Board: ... in the People,s Republic of China ("PRC"), ... in the development of,isosorbide mononitrate sustained release ... and treatment of angina., Based on ...
Cached Medicine Technology:Molecular Therapy Succeeds in Preventing Craniofacial Birth Defect in Mice 2Lotus Pharmaceuticals, Inc. Achieves Significant Milestones in the Development of Isosorbide Mononitrate Sustained Release Tablets 2Lotus Pharmaceuticals, Inc. Achieves Significant Milestones in the Development of Isosorbide Mononitrate Sustained Release Tablets 3
... incubators hold rotators and agitators ... can be set at 22C ... to 40C (59F to 104F). ... top to bottom. Recorder is ...
... Platelet incubators hold rotators and ... temperature can be set at ... 15C to 40C (59F to ... from top to bottom. Recorder ...
This model of bench top refrigerated incubator has been designed to suit the TPS-32 platelet shaker....
An enzyme-linked immuno-sorbent assay for the detection and quantitation of anti-tissue Transglutaminase in serum of patients with Celiac Disease and Dermatitis Herpetiformis....
Medicine Products: